Valproic acid induces non-apoptotic cell death mechanisms in multiple myeloma cell lines

International Journal of Oncology

Volumn 30, Issue 3, 2007, Pages 573-582

  Schwartz, Chantal ^a   Palissot, Valerie ^a   Aouali, Nassera ^a   Wack, Severine ^a   Brons, N H C ^a   Leners, Bernadette ^a   Bosseler, Manon ^a   Berchem, Guy ^b  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Cell death; Multiple myeloma; Valproic acid

Indexed keywords

CADAVERINE; CASPASE; CD45 ANTIGEN; DANSYLCADAVERINE; DNA FRAGMENT; DRUG DERIVATIVE; ENZYME INHIBITOR; PROPIDIUM IODIDE; VALPROIC ACID;

APOPTOSIS; ARTICLE; BIOSYNTHESIS; CARCINOMA; CELL CYCLE; CELL DEATH; CELL SURVIVAL; HUMAN; METABOLISM; MULTIPLE MYELOMA; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD45; APOPTOSIS; CADAVERINE; CARCINOMA; CASPASES; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; CELL SURVIVAL; DNA FRAGMENTATION; ENZYME INHIBITORS; HUMANS; MULTIPLE MYELOMA; PROPIDIUM; VALPROIC ACID;

EID: 33947726288     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.3.573     Document Type: Article

References (53)

1. Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med 351: 1860-1873, 2004.
2. Proskuryakov SY, Konoplyannikov AG and Gabai VL: Necrosis: a specific form of programmed cell death? Exp Cell Res 283: 1-16, 2003.
3. Lockshin RA and Zakeri ZÖ: Caspase-independent cell death? Oncogene 23: 2766-2773, 2004.
4. Jaattela M and Tschopp J: Caspase-independent cell death in T lymphocytes. Nat Immunol 4: 416-423, 2003.
5. Hirsch T, Marchetti P, Susin SA, et al: The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 15: 1573-1581, 1997.
6. Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene 23: 2891-2906, 2004. (Pubitemid 38638851)
7. Schmitt CA: Senescence, apoptosis and therapy - cutting the lifelines of cancer. Nat Rev Cancer 3: 286-295, 2003. (Pubitemid 37328864)
8. Roninson IB, Broude EV and Chang BD: If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4: 303-313, 2001.
9. Cheung P, Allis CD and Sassone-Corsi P: Signaling to chromatin through histone modifications. Cell 103: 263-271, 2000.
10. Coffey DC, Kutko MC, Glick RD, et al: The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 61: 3591-3594, 2001.
11. Marks PA, Richon VM, Breslow R and Rifkind RA: Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol 13: 477-483, 2001. (Pubitemid 33027900)
12. Cinatl J Jr, Cinatl J, Driever PH, et al: Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs 8: 958-963, 1997.
13. Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS: Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64: 1079-1086, 2004. (Pubitemid 38176913)
14. Gottlicher M: Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 83 (suppl 1): S91-S92, 2004.
15. Phillips A, Bullock T and Plant N: Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO. Toxicology 192: 219-227, 2003. (Pubitemid 37314020)
16. Thelen P, Schweyer S, Hemmerlein B, Wuttke W, Seseke F and Ringert RH: Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol 24: 25-31, 2004.
17. Tittle TV, Schaumann BA, Rainey JE and Taylor K: Segregation of the growth slowing effects of valproic acid from phenytoin and carbamazepine on lymphoid tumor cells. Life Sci 50: PL79-PL83, 1992.
18. Tang R, Faussat AM, Majdak P, et al: Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Leukemia 18: 1246-1251, 2004.
19. Kawagoe R, Kawagoe H and Sano K: Valproic acid induces apoptosis in human leukemia cells by stimulating both caspase-dependent and -independent apoptotic signaling pathways. Leuk Res 26: 495-502, 2002.
20. Roehm NW, Rodgers GH, Hatfield SM and Glasebrook AL: An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J Immunol Methods 142: 257-265, 1991.
21. Dimri GP, Lee X, Basile G, et al: A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92: 9363-9367, 1995.
22. McCarthy RC and Fetterhoff TJ: Issues for quality assurance in clinical flow cytometry. Arch Pathol Lab Med 113: 658-666, 1989.
23. Martin SJ, Reutelingsperger CP, McGahon AJ, et al: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545-1556, 1995.
24. Chang BD, Xuan Y, Broude EV, et al: Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene 18: 4808-4818, 1999.
25. Chang BD, Broude EV, Dokmanovic M, et al: A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res 59: 3761-3767, 1999.
26. Eom YW, Kim MA, Park SS, et al: Two distinct modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24: 4765-4777, 2005.
27. Shao Y, Gao Z, Marks PA and Jiang X: Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci USA 101: 18030-18035, 2004.
28. Insinga A, Minucci S and Pelicci PG: Mechanisms of selective anticancer action of histone deacetylase inhibitors. Cell Cycle 4: 741-743, 2005.
29. Chen YH, Lavelle D, De Simone J, Uddin S, Platanias LC and Hankewych M: Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). Blood 94: 251-259, 1999.
30. Lavelle D, Chen YH, Hankewych M and De Simone J: Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68: 170-178, 2001.
31. Gottlicher M, Minucci S, Zhu P, et al: Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978, 2001.
32. Warrell RP Jr, He LZ, Richon V, Calleja E and Pandolfi PP: Therapeutic targeting of transcription in acute promyelocytic leukemia brabley use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90: 1621-1625, 1998.
33. Place RF, Noonan EJ and Giardina C: HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 6: 37, 2005.
34. Xu WS, Perez G, Ngo L, Gui CY and Marks PA: Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res 65: 7832-7839, 2005.
35. Marks PA and Dokmanovic M: Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497-1511, 2005.
36. Insinga A, Monestiroli S, Ronzoni S, et al: Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 11: 71-76, 2005.
37. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM and Lau CC: Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther 4: 1912-1922, 2005.
38. Kaiser M, Zavrski I, Sterz J, et al: The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91: 248-251, 2006.
39. Bossy-Wetzel E and Green DR: Detection of apoptosis by annexin V labeling. Methods Enzymol 322: 15-18, 2000.
40. Brouckaert G, Kalai M, Krysko DV, et al: Phagocytosis of necrotic cells by macrophages is phosphatidylserine dependent and does not induce inflammatory cytokine production. Mol Biol Cell 15: 1089-1100, 2004.
41. Ishikawa H, Tsuyama N, Liu S, et al: Accelerated proliferation of myeloma cells by interleukin-6 cooperating with fibroblast growth factor receptor 3-mediated signals. Oncogene 24: 6328-6332, 2005.
42. Moreau P, Robillard N, Avet-Loiseau H, et al: Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 89: 547-551, 2004.
43. Asosingh K, De Raeve H, Menu E, et al: Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. Blood 103: 3131-3137, 2004.
44. Liu S, Ishikawa H, Tsuyama N, et al: Increased susceptibility to apoptosis in CD45(+) myeloma cells accompanied by the increased expression of VDAC1. Oncogene 25: 419-429, 2006.
45. Pei XY, Dai Y and Grant S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839-3852, 2004. (Pubitemid 38697620)
46. Ito K, Nakazato T, Xian MJ, et al: 1'-acetoxychavicol acetate is a novel nuclear factor kappaB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 65: 4417-4424, 2005.
47. Nakamura S, Kobayashi M, Shibata K, et al: Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells. Leuk Res 30: 123-135, 2006.
48. Hideshima T, Catley L, Yasui H, et al: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062, 2006.
49. Edinger AL and Thompson CB: Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 16: 663-669, 2004. (Pubitemid 39463117)
50. Yu L, Lenardo MJ and Baehrecke EH: Autophagy and caspases: a new cell death program. Cell Cycle 3: 1124-1126, 2004. (Pubitemid 40268628)
51. Mills KR, Reginato M, Debnath J, Queenan B and Brugge JS: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is required for induction of autophagy during lumen formation in vitro. Proc Natl Acad Sci USA 101: 3438-3443, 2004. (Pubitemid 38338213)
52. Martin DN and Baehrecke EH: Caspases function in autophagic programmed cell death in Drosophila. Development 131: 275-284, 2004. (Pubitemid 38181368)
53. Lee CY and Baehrecke EH: Steroid regulation of autophagic programmed cell death during development. Development 128: 1443-1455, 2001.